- Brand names:
- Pharmaceutical Company:
- Condition/Indication:
- Meeting Date: November 2018
- Public Summary Document (PSD) November 2018 PBAC Meeting - PDF
- Public Summary Document (PSD) November 2018 PBAC Meeting - Word
Encorafenib and binimetinib – November 2018
Encorafenib and Binimetinib: encorafenib: capsule 50 mg, capsule 75 mg; binimetinib: tablet 15 mg; B
Last updated
1 March 2019